
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$167.22
−$7.64 · -4.37%
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Previous close
$167.22
−$7.64 · -4.37%
Pre-market
$167.22
$0.00 · 0.00%
Oct 8, 7:36 AM ET
Regular session · ET · Market data may be delayed.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Day range
Current $167.22
52-week range
Current $167.22
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
16
Overpriced
Sentiment
67
Bullish
Risk
46
Elevated Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Day range
Current $167.22
52-week range
Current $167.22
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 738.26M USD | 634.44M USD | 632.36M USD | 801.54M USD | 670.53M USD |
| Cost of goods sold | 390.63M USD | 359.79M USD | 353.92M USD | 345.83M USD | 279.28M USD |
| Gross profit | 347.62M USD | 274.65M USD | 278.44M USD | 455.71M USD | 391.25M USD |
| Research and development | 54.18M USD | 43.2M USD | 42.72M USD | 43.94M USD | 34.27M USD |
| Selling, general, and administrative | 290.51M USD | 263.37M USD | 218.58M USD | 215.83M USD | 183.87M USD |
| Operating expenses | 288.05M USD | 309.76M USD | 230.74M USD | 231.04M USD | 224.01M USD |
| Interest income | 27.57M USD | — | — | 6.98M USD | 176K USD |
| Interest expense | 23.17M USD | 22.57M USD | 10.03M USD | 2.98M USD | 12.71M USD |
| Depreciation and amortization | 96.96M USD | 86.56M USD | 86.11M USD | 57.01M USD | 38.45M USD |
| Operating income | 59.58M USD | −35.11M USD | 47.7M USD | 224.67M USD | 167.25M USD |
| Net income | 48.89M USD | −25.51M USD | 35.6M USD | 185.96M USD | 128.29M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI308.01M0.01%2.3T USD0.03%$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB223.15M0.12%185.3B USD0.03%$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK128.1M0.28%44.7B USD0.05%$342.24-1.50%
Vanguard Extended Market ETFVXF111.55M0.11%95.4B USD0.05%$233.49-1.56%
First Trust NYSE Arca Biotechnology Index FundFBT109.76M3.80%2.89B USD0.55%$263.49-0.56%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY73.08M0.28%25.98B USD0.23%$663.94-1.64%
iShares Biotechnology ETFIBB70.5M0.68%10.4B USD0.44%$203.34+0.12%
Dimensional - US Small Cap ETFDFAS69.31M0.20%33.66B USD0.31%$77.92-1.38%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
First Trust NYSE Arca Biotechnology Index FundFBT
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares Biotechnology ETFIBB
Dimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.